The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

The concern of endophthalmitis is casting a larger spector over the treatment of ocular conditions with intravitreal injection. Bevacizumab is typically obtained through such compounding ...

Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections ...

FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

A new study published in the International Journal of Ophthalmology showed specific optical coherence tomography (OCT) ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or ‘wet’ age-related macular ...

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.